The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia

Neurobiology of Disease

Volumn 118, Issue , 2018, Pages 64-75

  Rojo Bustamante, Estefania ^a,b,j   Abellanas, Miguel Angel ^a,b   Clavero, Pedro ^c,d   Thiolat, Marie Laure ^e,f   Li, Qin ^g,h   Luquin, Maria Rosario ^b,d,i   Bezard, Erwan ^e,f,g,h   Aymerich, Maria S ^a,b,d  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c Instituto de Investigación Sanitaria de Navarra   (Spain)

^d IdiSNA Navarra Institute for Health Research   (Spain)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

^g Williams House   (United Kingdom)

^h INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

ⁱ UNIVERSITY CLINIC OF NAVARRA   (Spain)

^j UNIVERSIDAD DE MANIZALES   (Colombia)

more..

Author keywords

Cannabinoids; Endocannabinoid system; Levodopa induced dyskinesia; Parkinson's disease

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; ACYLGLYCEROL; ARACHIDONIC ACID DERIVATIVE; ENDOCANNABINOID; GLYCERYL 2-ARACHIDONATE; LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; DOWN REGULATION; ENZYME DEGRADATION; ENZYME SYNTHESIS; EXTERNAL SEGMENT OF THE GLOBUS PALLIDUS; GLOBUS PALLIDUS; INTERNAL SEGMENT OF THE GLOBUS PALLIDUS; LEVODOPA-INDUCED DYSKINESIA; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PUTAMEN; REAL TIME POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; UPREGULATION; ANIMAL; BIOSYNTHESIS; DRUG EFFECT; DYSKINESIA; FEMALE; GENE EXPRESSION; GENETICS; MACACA FASCICULARIS; METABOLISM; PARKINSONISM;

ANIMALS; ARACHIDONIC ACIDS; BASAL GANGLIA; DYSKINESIA, DRUG-INDUCED; ENDOCANNABINOIDS; FEMALE; GENE EXPRESSION; GLYCERIDES; LEVODOPA; MACACA FASCICULARIS; MALE; PARKINSONIAN DISORDERS; RECEPTOR, CANNABINOID, CB1;

EID: 85049468504     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2018.06.019     Document Type: Article

References (56)

1. Adermark, L., Talani, G., Lovinger, D.M., Endocannabinoid-dependent plasticity at GABAergic and glutamatergic synapses in the striatum is regulated by synaptic activity. Eur. J. Neurosci. 29 (2009), 32–41, 10.1111/j.1460-9568.2008.06551.x.
2. Azkona, G., Marcilla, I., López De Maturana, R., Sousa, A., Pérez-Navarro, E., Luquin, M.-R., Sanchez-Pernaute, R., Azkona, G., López De Maturana, R., Sousa, A., Sanchez-Pernaute, R., Marcilla, I., Luquin, R., Pérez-Navarro, E., Pérez-Navarro Institut, E., Biomèdiques August Pi Sunyer, I., Pi Sunyer, A., Sustained increase of PKA activity in the Postcommissural putamen of Dyskinetic monkeys. Mol. Neurobiol. 50 (2014), 1131–1141, 10.1007/s12035-014-8688-7.
3. Bastide, M.F., Meissner, W.G., Picconi, B., Fasano, S., Fernagut, P.-O., Feyder, M., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., Fisone, G., Jon Stoessl, A., Bourdenx, M., Engeln, M., Navailles, S., De Deurwaerdère, P., Ko, W.K.D., Simola, N., Morelli, M., Groc, L., Rodriguez, M.-C., Gurevich, E.V., Quik, M., Morari, M., Mellone, M., Gardoni, F., Tronci, E., Guehl, D., Tison, F., Crossman, A.R., Kang, U.J., Steece-Collier, K., Fox, S., Carta, M., Angela Cenci, M., Bézard, E., Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Prog. Neurobiol. 132 (2015), 96–168, 10.1016/j.pneurobio.2015.07.002.
4. Bezard, E., Dovero, S., Prunier, C., Ravenscroft, P., Chalon, S., Guilloteau, D., Crossman, A.R., Bioulac, B., Brotchie, J.M., Gross, C.E., Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci. 21 (2001), 6853–6861.
5. Blankman, J.L., Simon, G.M., Cravatt, B.F., A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 14 (2007), 1347–1356, 10.1016/j.chembiol.2007.11.006.
6. Cadas, H., di Tomaso, E., Piomelli, D., Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J. Neurosci. 17 (1997), 1226–1242.
7. Castillo, P.E., Younts, T.J., Chá Vez, A.E., Hashimotodani, Y., Endocannabinoid signaling and synaptic function. Neuron 76 (2012), 70–81, 10.1016/j.neuron.2012.09.020.
8. Celorrio, M., Fernández-Suárez, D., Rojo-Bustamante, E., Echeverry-Alzate, V., Ramírez, M.J., Hillard, C.J., López-Moreno, J.A., Maldonado, R., Oyarzábal, J., Franco, R., Aymerich, M.S., Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease. Brain Behav. Immun., 57, 2016, 10.1016/j.bbi.2016.06.010.
9. Cotzias, G.C., Papavasiliou, P.S., Gellene, R., Modification of parkinsonism? Chronic treatment with L-Dopa. N. Engl. J. Med. 280 (1967), 337–345, 10.1056/NEJM196902132800701.
10. Cravatt, B.F., Giang, D.K., Mayfield, S.P., Boger, D.L., Lerner, R.A., Gilula, N.B., Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384 (1996), 83–87, 10.1038/384083a0.
11. Cravatt, B.F., Demarest, K., Patricelli, M.P., Bracey, M.H., Giang, D.K., Martin, B.R., Lichtman, A.H., Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. 98 (2001), 9371–9376, 10.1073/pnas.161191698.
12. Cristino, L., Starowicz, K., De Petrocellis, L., Morishita, J., Ueda, N., Guglielmotti, V., Di Marzo, V., Immunohistochemical localization of anabolic and catabolic enzymes for anandamide and other putative endovanilloids in the hippocampus and cerebellar cortex of the mouse brain. Neuroscience 151 (2008), 955–968, 10.1016/j.neuroscience.2007.11.047.
13. van der Stelt, M., Fox, S.H., Hill, M., Crossman, A.R., Petrosino, S., Di Marzo, V., Brotchie, J.M., A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. FASEB J. 19 (2005), 1140–1142, 10.1096/fj.04-3010fje.
14. Devane, W.A., Hanus, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., Mechoulam, R., Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992), 1946–1949.
15. Di Marzo, V., Hill, M.P., Bisogno, T., Crossman, A.R., Brotchie, J.M., Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J. 14 (2000), 1432–1438.
16. dos-Santos-Pereira, M., da-Silva, C.A., Guimarães, F.S., Del-Bel, E., Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: possible mechanism of action. Neurobiol. Dis. 94 (2016), 179–195, 10.1016/j.nbd.2016.06.013.
17. Egertová M., Simon, G.M., Cravatt, B.F., Elphick, M.R., Localization of N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) expression in mouse brain: a new perspective on N-acylethanolamines as neural signaling molecules. J. Comp. Neurol. 506 (2008), 604–615, 10.1002/cne.21568.
18. Engeln, M., De Deurwaerdère, P., Li, Q., Bezard, E., Fernagut, P.-O., Widespread Monoaminergic dysregulation of both motor and non-motor circuits in parkinsonism and dyskinesia. Cereb. Cortex 25 (2015), 2783–2792, 10.1093/cercor/bhu076.
19. Fernández-Ruiz, J., The endocannabinoid system as a target for the treatment of motor dysfunction. Br. J. Pharmacol. 156 (2009), 1029–1040, 10.1111/j.1476-5381.2008.00088.x.
20. Fernández-Ruiz, J., Romero, J., Velasco, G., Tolón, R.M., Ramos, J.A., Guzmán, M., Cannabinoid CB2 receptor: a new target for controlling neural cell survival?. Trends Pharmacol. Sci. 28 (2007), 39–45, 10.1016/J.TIPS.2006.11.001.
21. Fernández-Suárez, D., Celorrio, M., Lanciego, J.L., Franco, R., Aymerich, M.S., Loss of Parvalbumin-positive neurons from the Globus Pallidus in animal models of Parkinson disease. J. Neuropathol. Exp. Neurol. 71 (2012), 973–982, 10.1097/NEN.0b013e3182717cba.
22. Fox, S.H., Henry, B., Hill, M., Crossman, A., Brotchie, J., Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov. Disord. 17 (2002), 1180–1187, 10.1002/mds.10289.
23. Fox, S.H., Katzenschlager, R., Lim, S.-Y., Ravina, B., Seppi, K., Coelho, M., Poewe, W., Rascol, O., Goetz, C.G., Sampaio, C., The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov. Disord. 26 (2011), S2–S41, 10.1002/mds.23829.
24. Freund, T.F., Katona, I., Piomelli, D., Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 83 (2003), 1017–1066, 10.1152/physrev.00004.200383/3/1017 (pii).
25. Gao, Y., Vasilyev, D.V., Goncalves, M.B., Howell, F.V., Hobbs, C., Reisenberg, M., Shen, R., Zhang, M.-Y., Strassle, B.W., Lu, P., Mark, L., Piesla, M.J., Deng, K., Kouranova, E.V., Ring, R.H., Whiteside, G.T., Bates, B., Walsh, F.S., Williams, G., Pangalos, M.N., Samad, T.A., Doherty, P., Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J. Neurosci. 30 (2010), 2017–2024, 10.1523/JNEUROSCI.5693-09.2010.
26. García, C., Palomo-Garo, C., Gómez-Gálvez, Y., Fernández-Ruiz, J., Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia. Br. J. Pharmacol. 173 (2016), 2069–2079, 10.1111/bph.13215.
27. Gerdeman, G.L., Ronesi, J., Lovinger, D.M., Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat. Neurosci. 5 (2002), 446–451, 10.1038/nn832.
28. Gómez-Gálvez, Y., Palomo-Garo, C., Fernández-Ruiz, J., García, C., Potential of the cannabinoid CB 2 receptor as a pharmacological target against inflammation in Parkinson's disease. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 64 (2016), 200–208, 10.1016/j.pnpbp.2015.03.017.
29. González-Aparicio, R., Moratalla, R., Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson's disease. Neurobiol. Dis. 62 (2014), 416–425, 10.1016/j.nbd.2013.10.008.
30. Gulyas, A.I., Cravatt, B.F., Bracey, M.H., Dinh, T.P., Piomelli, D., Boscia, F., Freund, T.F., Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur. J. Neurosci. 20 (2004), 441–458, 10.1111/j.1460-9568.2004.03428.x.
31. Hashimotodani, Y., Ohno-Shosaku, T., Kano, M., Presynaptic monoacylglycerol lipase activity determines basal endocannabinoid tone and terminates retrograde endocannabinoid signaling in the Hippocampus. J. Neurosci. 27 (2007), 1211–1219, 10.1523/JNEUROSCI.4159-06.2007.
32. Hurley, M.J., Mash, D.C., Jenner, P., Expression of cannabinoid CB 1 receptor mRNA in basal ganglia of normal and parkinsonian human brain. J. Neural Transm. 110 (2003), 1279–1288, 10.1007/s00702-003-0033-7.
33. Katona, I., Urbán, G.M., Wallace, M., Ledent, C., Jung, K.-M., Piomelli, D., Mackie, K., Freund, T.F., Molecular composition of the endocannabinoid system at glutamatergic synapses. J. Neurosci. 26 (2006), 5628–5637, 10.1523/JNEUROSCI.0309-06.2006.
34. Kreitzer, A.C., Malenka, R.C., Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 445 (2007), 643–647, 10.1038/nature05506.
35. Lafourcade, M., Elezgarai, I., Mato, S., Bakiri, Y., Grandes, P., Manzoni, O.J., Molecular components and functions of the endocannabinoid system in mouse prefrontal cortex. PLoS One, 2, 2007, e709, 10.1371/journal.pone.0000709.
36. Lastres-Becker, I., Cebeira, M., de Ceballos, M.L., Zeng, B.Y., Jenner, P., Ramos, J.A., Fernandez-Ruiz, J.J., Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur. J. Neurosci. 14 (2001), 1827–1832 (PMID: 11860478).
37. Martin, R.F., Bowden, D.M., A stereotaxic template atlas of the macaque brain for digital imaging and quantitative neuroanatomy. NeuroImage 4 (1996), 119–150, 10.1006/nimg.1996.0036.
38. Martinez, A.A., Morgese, M.G., Pisanu, A., Macheda, T., Paquette, M.A., Seillier, A., Cassano, T., Carta, A.R., Giuffrida, A., Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats. Neurobiol. Dis. 74 (2015), 295–304, 10.1016/j.nbd.2014.11.024.
39. Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N.E., Schatz, A.R., Gopher, A., Almog, S., Martin, B.R., Compton, D.R., Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50 (1995), 83–90.
40. Morgese, M.G., Cassano, T., Cuomo, V., Giuffrida, A., Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. Exp. Neurol. 208 (2007), 110–119, 10.1016/j.expneurol.2007.07.021.
41. Navarrete, F., García-Gutiérrez, M.S., Aracil-Fernández, A., Lanciego, J.L., Manzanares, J., Cannabinoid CB1 and CB2 receptors, and Monoacylglycerol lipase gene expression alterations in the basal ganglia of patients with Parkinson's disease. Neurotherapeutics, 2018, 10.1007/s13311-018-0603-x.
42. Obeso, J.A., Rodriguez-Oroz, M.C., Javier Blesa, F., Guridi, J., The globus pallidus pars externa and Parkinson's disease. Ready for prime time?. Exp. Neurol. 202 (2006), 1–7, 10.1016/j.expneurol.2006.07.004.
43. Okamoto, Y., Wang, J., Morishita, J., Ueda, N., Biosynthetic pathways of the Endocannabinoid Anandamide. Chem. Biodivers. 4 (2007), 1842–1857, 10.1002/cbdv.200790155.
44. Pertwee, R.G., Howlett, A.C., Abood, M.E., Alexander, S.P.H., Di Marzo, V., Elphick, M.R., Greasley, P.J., Hansen, H.S., Kunos, G., Mackie, K., Mechoulam, R., Ross, R.A., International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol. Rev. 62 (2010), 588–631, 10.1124/pr.110.003004.
45. Redgrave, P., Rodriguez, M., Smith, Y., Rodriguez-Oroz, M.C., Lehericy, S., Bergman, H., Agid, Y., Delong, M.R., Obeso, J.A., Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease. Nat. Rev. Neurosci. 11 (2010), 760–772, 10.1038/nrn2915.
46. Rohlfing, T., Kroenke, C.D., Sullivan, E.V., Dubach, M.F., Bowden, D.M., Grant, K.A., Pfefferbaum, A., The INIA19 template and NeuroMaps atlas for primate brain image parcellation and spatial normalization. Front. Neuroinform., 6, 2012, 27, 10.3389/fninf.2012.00027.
47. Romero, J., Berrendero, F., Pérez-Rosado, A., Manzanares, J., Rojo, A., Fernández-Ruiz, J.J., de Yebenes, J.G., Ramos, J.A., Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen. Life Sci. 66 (2000), 485–494.
48. Santini, E., Sgambato-Faure, V., Li, Q., Savasta, M., Dovero, S., Fisone, G., Bezard, E., Distinct changes in cAMP and extracellular signal- regulated protein kinase Signalling in L-DOPA-induced dyskinesia. PLoS One, 5, 2010, e12322, 10.1371/journal.pone.0012322.
49. Sañudo-Peña, M.C., Tsou, K., Walker, J.M., Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci. 65 (1999), 703–713.
50. Sieradzan, K.A., Fox, S.H., Hill, M., Dick, J.P., Crossman, A.R., Brotchie, J.M., Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 57 (2001), 2108–2111, 10.1212/WNL.57.11.2108.
51. Stella, N., Schweitzer, P., Piomelli, D., A second endogenous cannabinoid that modulates long-term potentiation. Nature 388 (1997), 773–778, 10.1038/42015.
52. Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., Waku, K., 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215 (1995), 89–97.
53. Tanimura, A., Yamazaki, M., Hashimotodani, Y., Uchigashima, M., Kawata, S., Abe, M., Kita, Y., Hashimoto, K., Shimizu, T., Watanabe, M., Sakimura, K., Kano, M., The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. Neuron 65 (2010), 320–327, 10.1016/j.neuron.2010.01.021.
54. Van Laere, K., Casteels, C., Lunskens, S., Goffin, K., Grachev, I.D., Bormans, G., Vandenberghe, W., Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo. Neurobiol. Aging 33 (2012), 620.e1–620.e8, 10.1016/j.neurobiolaging.2011.02.009.
55. Walsh, S., Mnich, K., Mackie, K., Gorman, A.M., Finn, D.P., Dowd, E., Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat. Brain Res. Bull. 81 (2010), 543–548, 10.1016/j.brainresbull.2010.01.009.
56. Zeng, B.Y., Dass, B., Owen, A., Rose, S., Cannizzaro, C., Tel, B.C., Jenner, P., Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats. Neurosci. Lett. 276 (1999), 71–74.